Delivery Order SPE2DB22D9239-SPE2DB24FDL36

Award Date 8/1/24
Potential Completion Date 8/22/24
Potential Value $58K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $17,388.80 firm fixed-price delivery order is for the supply of 1,000 unit vials of Kcentra, a blood coagulation factor medication, with a performance period through September 18, 2024. This award is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $18,896.64 contract is for the delivery of 1,000 units of the specialized medication Kcentra by January 8, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a wide range...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,609.92, is for the delivery of 1,000-unit vials of the medication Kcentra, with a period of performance through May 17, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $13,740.80, is for the delivery of 500-unit vials of the medication Kcentra. The award is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,448.32 contract is for the delivery of 1,000 unit vials of the medication Kcentra by February 14, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide...
This contract was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $20,592.96, is for the delivery of 1,000 unit vials of the drug KCENTRA. The contract is a firm fixed-price delivery order, with an ultimate completion date of June 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $13,655.68 order is for 1,000 unit vials of the drug Kcentra, with a performance period through August 7, 2024. The award is made under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with the DLA, which allows the agency to place orders for a wide range of pharmaceutical products and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $9,758.40 contract is for the delivery of 500-unit vials of the medication Kcentra to support the medical supply needs of military healthcare facilities. The contract has a period of performance through March 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. also holds a...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, for the delivery of 1,000 unit vials of the biologic medication KCENTRA. The contract has a firm fixed-price, delivery order type, with a ceiling value of $58,453.12 and a period of performance through May 13, 2024. The contract is not associated with a set-aside...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of 4,565,252,938 units of KCENTRA 1,000 unit vials. The $34,139.20 contract has an ultimate completion date of August 13, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of medications and medical supplies to support the...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDL36
    Delivery Order

This federal contract award is for a delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of 1,000 unit vials of the medication Kcentra, with a total ceiling value of $58,140.00. The contract is a firm fixed-price delivery order with no set-aside designation, and it has an ultimate completion date of August 22, 2024.

DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. Through this vehicle, DMS Pharmaceutical Group provides both routine and critical medications to support the diverse medical needs of military personnel and their dependents across various Department of Defense healthcare facilities.

Generated 10/31/24, 9:07 AM